Research · Corneal Cross-Linking · 26 June 2026
Cross-linking biomaterials and the future of keratoconus, infectious keratitis and myopia care
Corneal cross-linking has become one of the most important advances in modern eye care. A sweeping new review co-authored by the ELZA Institute charts how corneal cross-linking has grown from a single rescue therapy into a fast-moving field of engineered biomaterials — and where eye care goes from here.
For two decades, one of the most quietly transformative treatments in eye care has rested on a deceptively simple idea: if you can stiffen the cornea, you can stop a sight-threatening disease in its tracks. That idea — corneal cross-linking (CXL) — began as a single treatment for keratoconus, a condition in which the cornea progressively thins and bulges into an irregular cone. A new review in Progress in Retinal and Eye Research, co-authored by ELZA Institute researchers, charts how that one procedure has grown into a sprawling field of engineered biomaterials.
The basic recipe is now textbook, and ELZA helped write it. Clinicians soak the cornea in riboflavin (vitamin B₂) and shine ultraviolet-A light on it. The light excites the riboflavin, generating reactive oxygen species that forge fresh chemical bonds between the collagen fibres of the corneal stroma. The result is a stiffer, more stable cornea. The classic “epithelium-off” Dresden protocol, introduced in 2003, remains the benchmark, with 15-year data confirming it halts keratoconus in the great majority of treated eyes. You can read more about how the procedure works on our corneal cross-linking treatment page.
Corneal cross-linking beyond keratoconus: infections and myopia
The review makes clear the field has moved well beyond that founding formula. Cross-linking is now used not only for keratoconus but for ectasia that can follow laser refractive surgery, and — as PACK-CXL — as a treatment for infectious keratitis, where ultraviolet light and riboflavin help disable invading microbes and blunt the enzymes that destroy corneal tissue. Perhaps most strikingly, the same biomechanical logic is being turned to the back of the eye: scleral cross-linking is being explored to rigidify the sclera and slow the runaway elongation that drives high myopia, a condition projected to affect roughly half the world’s population by 2050.
A wave of new cross-linking biomaterials
Much of the recent innovation, the authors argue, is really materials science. They organise the expanding toolkit into three families: physical (light-activated), chemical, and enzymatic cross-linking. Riboflavin still anchors the photochemical approach, but newer photosensitisers — Rose Bengal, the near-infrared agent WST-11, verteporfin and even graphitic carbon nitride quantum dots — offer deeper tissue penetration or built-in oxygen generation. Plant-derived chemical agents such as genipin promise cross-linking without ultraviolet light, an attraction for thin corneas. Enzymatic strategies that mimic the body’s own collagen-stabilising machinery are advancing too; one copper-based lysyl oxidase activator, IVMED-80, has reached Phase 2 trials as a potential non-surgical, drop-based alternative.
Smarter delivery, deeper into the eye
Getting these agents to the right place is its own challenge. Because the intact corneal epithelium is a formidable barrier, researchers are testing permeation enhancers, iontophoresis, sonophoresis, nanoparticles, metal-organic frameworks, hydrogels and microneedle arrays to load riboflavin precisely into the stroma. Oxygen — a rate-limiting ingredient in the reaction — is being managed with supplemental delivery, pulsed light and oxygen-releasing microneedles. In one striking demonstration, a wireless, battery-free ocular patch delivered riboflavin to the posterior sclera and activated cross-linking with a tiny LED, boosting scleral stiffness by 151 percent.
From one-size-fits-all to precision eye care
For all this momentum, the review is candid about the hurdles: many impressive results come from laboratory or animal models, treatments must constantly balance efficacy against safety, and the field still lacks standardised metrics for judging success. The authors’ broader message is one of transition. Cross-linking is shifting toward precision, data-driven treatment — topography-guided irradiation that concentrates strengthening exactly where a cornea is weakest, real-time theranostic monitoring, portable and even wearable devices, and AI to tailor dose and timing to the individual eye. The future “gold standard,” they conclude, will not be a fixed protocol but a flexible, biomaterial-enabled framework for sculpting the eye’s mechanical properties — strengthening tissue while keeping it safe.
Read the full paper — free access: “Cutting-edge cross-linking biomaterials advancing ophthalmic therapeutics,” published in Progress in Retinal and Eye Research (2026).
Read or download the full article on ScienceDirect → (free access until 15 August 2026 — no registration required).
